Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers-Reference-Cited by-同舟云学术

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

Published:2017-03-30 Issue:26 Volume:8 Page:41932-41946
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Broos Katrijn¹,Keyaerts Marleen²³,Lecocq Quentin¹,Renmans Dries¹,Nguyen Tham²⁴,Escors David⁵,Liston Adrian⁶⁷,Raes Geert⁴⁸,Breckpot Karine¹,Devoogdt Nick²

Affiliation:

1. Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, B-1090 Brussels, Belgium

2. In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, B-1090 Brussels, Belgium

3. Nuclear Medicine Department, UZ Brussel, B-1090 Brussels, Belgium

4. Unit of Cellular and Molecular Immunology (CMIM), Vrije Universiteit Brussel, B-1050 Brussels, Belgium

5. Immunomodulation Group, Navarrabiomed-Biomedical Research Centre, 31008 Pamplona, Navarra, Spain

6. Department of Microbiology and Immunology, University of Leuven (KU Leuven), 3000 Leuven, Belgium

7. VIB Center for Brain and Disease Research, 3000 Leuven, Belgium

8. Myeloid Cell Immunology Laboratory, VIB Inflammation Research Center, 9052 Ghent, Belgium

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27

2. Application of 99mTc-Labeled WL12 Peptides as a Tumor PD-L1-Targeted SPECT Imaging Agent: Kit Formulation, Preclinical Evaluation, and Study on the Influence of Coligands;Pharmaceuticals;2024-07-08

3. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy;2024-05-08

4. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization;Frontiers in Immunology;2024-04-19

5. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel ^99mTc-Labeled Nanobody Tracer with Rapid Renal Clearance;Molecular Pharmaceutics;2024-02-23